CD274 and neoplasm: As the investigators found increased CD8+ T cell infiltration at patient tumor sites, as well as increased PD-L1 expression, they hoped to combine ONCOS-102 with checkpoint inhibitors and thus utilized the huNOG mouse model for preclinical testing to approximate the clinical setting.